KDNY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KDNY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Chinook Therapeutics's Investments And Advances for the quarter that ended in Jun. 2023 was $47.96 Mil.
Chinook Therapeutics's quarterly Investments And Advances declined from Dec. 2022 ($52.26 Mil) to Mar. 2023 ($50.86 Mil) and declined from Mar. 2023 ($50.86 Mil) to Jun. 2023 ($47.96 Mil).
Chinook Therapeutics's annual Investments And Advances increased from Dec. 2020 ($3.00 Mil) to Dec. 2021 ($117.62 Mil) but then declined from Dec. 2021 ($117.62 Mil) to Dec. 2022 ($52.26 Mil).
The historical data trend for Chinook Therapeutics's Investments And Advances can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chinook Therapeutics Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Investments And Advances | - | 3.00 | 117.62 | 52.26 |
Chinook Therapeutics Quarterly Data | ||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Investments And Advances | Get a 7-Day Free Trial | 89.13 | 70.73 | 52.26 | 50.86 | 47.96 |
Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.
Andrew James King | officer: Head of Renal Discovery | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
William Mariner Greenman | director | C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520 |
Eric Dobmeier | director, officer: President, CEO | C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Davis Jerel | director, 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Robert Azelby | director | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
Mahesh Krishnan | director | 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Andrew Oxtoby | officer: Chief Commercial Officer | 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005 |
Tom Frohlich | officer: Chief Business Officer | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
Eric Bjerkholt | officer: Chief Financial Officer | 132 PURDURE AVENUE, KENGSINGTON CA 94708 |
Dolca Thomas | director | C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Srinivas Akkaraju | director | 565 EVERETT AVENUE, PALO ALTO CA 94301 |
Alan Glicklich | officer: Chief Medical Officer | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
Versant Voyageurs I, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Voyageurs I Parallel, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Venture Capital Vii, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
From GuruFocus
By PRNewswire • 07-17-2023
By Marketwired • 07-11-2023
By ACCESSWIRE • 06-29-2023
By PRNewswire PRNewswire • 06-12-2023
By PRNewswire • 07-25-2023
By ACCESSWIRE ACCESSWIRE • 06-20-2023
By Business Wire Business Wire • 06-14-2023
By GlobeNewswire GlobeNewswire • 06-17-2023
By sperokesalga sperokesalga • 06-14-2023
By PRNewswire PRNewswire • 06-20-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.